US Brand Drug Price Inflation Slowing As Elections Approach
Executive Summary
Wholesalers attribute lower-than-expected earnings in part to moderating price increases for branded drugs and predict the trend will continue into 2017.
You may also be interested in...
Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics
Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.
Big Pharma’s Unlikely Price Pledge Leader
Allergan is taking a page from Big Pharma’s strategy two decades ago to fend off efforts at direct price regulation by pledging restraint on price increases. The differences in the pledge – and the image of the pledge maker – are instructive.
EpiPen Price Story Highlights Growing Impact Of Drug Deductibles
Nearly half of employer-sponsored insurance plans surveyed require members to meet a deductible before coverage for a prescription drug is approved.